|
Background: Allopurinol is widely used to prevent
hyperuricemia in patients with tumor lysis syndrome.
However, its use can trigger severe cutaneous adverse
reactions (SCARs) with a mortality rate of approximately
11.39%. The human leukocyte antigen (HLA)–B*58:01
genotype is a major risk factor for SCARs. Although most
studies to date have examined HLA–B*58:01 in Thai adults,
data on pediatric patients are limited.
Purpose: Here we aimed to evaluate the... |